Primary Immunodeficiencies: novel insights in pathogenesis and potential therapeutic approaches by Palamaro, Loredana
“FEDERICO II” 
UNIVERSITY OF NAPLES 
 
 
PhD Program 
“Human Reproduction, Development and Growth” 
 
 
 
Director 
Prof. Claudio Pignata 
 
 
PhD Thesis 
 
Primary Immunodeficiencies: novel 
insights in pathogenesis and potential 
therapeutic approaches 
 
 
Student          Tutor 
Dr. Loredana Palamaro                   Prof. Claudio Pignata 
 
 
 
Academic Year 2012-2013  
 
 
1 
 
 
INDEX  
  
Background and Aims  Pag.  3 
  
Chapter I: Thymus and T-cell development Pag.  6 
  
§ 1.1 T-cell development: focus on FOXN1 Pag.  8 
Publication  
  
§ 1.2 FOXN1 and human diseases Pag. 22 
Publication  
  
§ 1.3 New strategy to develop an in vitro thymic organoid Pag. 24 
§ 1.4 Conclusive remarks Pag. 34 
  
  
Chapter II: Impaired regulation of the immune system  Pag. 35 
  
§ 2.1 Abnormalities of the central and peripheral tolerance Pag. 36 
  
§ 2.1.1 Altered central tolerance and autoimmune disease Pag. 38 
Publications  
  
§ 2.1.2 Altered peripheral tolerance and autoimmune 
disease 
Pag. 71 
Publications  
  
§ 2.1.3 SCID-like phenotype associated with autoimmunity  Pag. 75 
Publication  
  
§ 2.2 T-helper 1 – T-helper 2 imbalance Pag. 80 
  
§ 2.2.1 Hyper IgE and IL12R deficiency Pag. 81 
Publications  
  
§ 2.3 Conclusive remarks Pag. 93 
  
  
Chapter III: Alteration of immune system genes: cancer 
predisposition and neurodegeneration 
 
Pag. 94 
  
§ 3.1 The role of γc in endocrine system and cancerogenesis Pag. 96 
Publications  
2 
 
§ 3.1.1 Potential oncogenic role of the γc Pag. 115 
  
§ 3.1.1.1 The γc provides spontaneous or induced cell 
proliferation 
Pag. 115 
Publication  
  
§ 3.1.1.2 Role of  γc on spontaneous cell cycle progression 
in human malignant cell-lines  
Pag. 124 
Publication  
  
§ 3.2 ATM and Hyper IgM: cancer predisposition and 
neurodegeneration  
Pag. 136 
Publications  
  
§ 3.3 Conclusive remarks Pag. 151 
  
  
Technologies Pag. 152 
  
References Pag. 162 
  
Summary Pag. 181 
  
Curriculum Vitae Pag. 183 
 
 
3 
 
BACKGROUND AND AIMS 
 
The immune system detect a wide variety of agents, from viruses to 
parasitic worms, and distinguish them from the organism’s own healthy 
tissue.  Disruption of any part of the orchestrated immune response can 
result in an inability to control infections and subsequent illness. Apart from 
physical barriers, the immune response is composed from a diverse network 
of defenses, including cellular components and soluble mediators. A proper 
immune response relies on the innate immunity, characterized by a rapid 
and nonspecific initial response to infections and later on the adaptive 
immunity, characterized by a specific response to a particular antigen. The 
innate immune response involves three major cell types: phagocytic cells, 
such as neutrophils and macrophages, natural killer (NK) cells and antigen 
presenting cells (APC), which are also involved in the induction of an 
adaptive immune response. The adaptive immune system includes T and B 
lymphocytes responsible for cellular and humoral responses, respectively.  
However, these components of the immune system act in a well 
orchestrated and integrated unique system in order to maintain a normal 
resistance to infections.  Failure of host defense cause the dysregulation of 
the immune system, in particular the onset of immunodeficiency, 
autoimmunity and cancer predisposition. 
Primary immunodeficiencies (PIDs) comprise more than 200 different 
disorders that affect the development and the functions of the immune 
system.  In most cases primary immunodeficiencies are monogenic 
disorders that follow a simple mendelian inheritance. Primary 
immunodeficiencies are rare and have an overall prevalence of 
approximately 1:10.000 live births and are classified according to the 
component of the immune system that is primarily involved [1].  Defects in 
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adaptive immune responses include antibody deficiency syndromes and 
combined immunodeficiencies (CIDs). Defects of innate immunity 
comprise disorders of phagocytes, Toll-like receptor (TLR)–mediated 
signaling, and complement. All of these forms are characterized by 
increased susceptibility to recurrent infections, severe infections, or both, 
with distinctive susceptibility to various types of pathogens depending on 
the nature of the immune defect. In addition, some forms of PIDs present 
with immune dysregulation, and others (immunodeficiency syndromes) 
have a more complex phenotype in which immunodeficiency is only one of 
multiple components of the disease phenotype [2]. 
PIDs are often associated with various autoimmune manifestations [2].  For 
many years autoimmunity and immune deficiency have been considered 
two opposite extremes of immune function but it is now clear that they 
represent intertwined phenomena that reflect inadequate immune function 
[3,4].  In these cases the autoimmunity does not seem to be related to a 
defect of tolerance to self-antigens, but rather to a persistent stimulation as a 
result of the inability to eradicate antigens [5].  This immune dysregulation 
leads to compensatory and exaggerated chronic inflammatory responses 
that result in tissue damage and autoimmunity.   
Moreover, primary immunodeficiencies are usually characterized by an 
increased susceptibility to cancer.  In the last decade cancer has become the 
most significant life-threatening complication of PIDs after infections [6,7].  
In fact the major life span observed in patients affected with PIDs thanks to 
the improvements in the prevention and treatment of infections also led to 
an increased incidence of malignancies.  A high cancer susceptibility has 
been reported for some types of PIDs, such as ataxia-telangiectasia (AT), 
common variable immunodeficiency (CVID), Wiskott-Aldrich Syndrome 
(WAS), SCID, selective IgA deficiency, DNA repair deficiencies and 
Hyper IgM Syndromes.  The main type of malignancy in PIDs is non 
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Hodgkin lymphoma, followed by Hodgkin lymphoma and leukemia [8].  
However, the type of malignancy depends on the specific PID, the age and 
the infective clinical history of the patients.  The genetic defect, underlying 
the immunodeficiency, may play a direct role in cancer pathogenesis either 
facilitating chronic infection, especially with oncogenic viruses such as 
Epstein Barr virus (EBV), or through genetic mutations in DNA double-
strand breaks repair systems, which lead to accumulation of mutations that 
promote tumorogenesis; the genetic defect can also play an indirect role in 
the tumor development which results from the break-down of normal 
immune surveillance of transformed cells [9,10]. 
This thesis reports the results obtained during my PhD course in 
“Human Reproduction, Development and Growth” (XXV Cycle) from 
March 2010 to March 2013.   
My PhD programme has been focused in the study of the following lines 
of research: 
 Study of the functional role of transcription factor FOXN1 in 
the T-cell ontogeny and molecular and clinical characterization 
of a primary T-cell immunodeficiency due to FOXN1gene 
mutation;  
 Study of an impaired regulation of the immune system; 
 Study of primary immunodeficiencies associated with cancer 
predisposition and neurodegeneration. 
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CHAPTER I 
“Thymus and T-cell development” 
 
The thymus provides the microenvironment essential for the development of T 
cells from  hematopoietic stem cells (HSCs) [11,12].  An important feature of the 
thymic microenvironment is its three-dimensional (3D) organization, consisting of 
an ordered architecture of thymic stromal cells (TSCs), that represent a 
heterogeneous mixture of cell types including cortical and medullary thymic 
epithelial cells (TECs), fibroblasts, endothelial cells, dendritic cells (DCs), and 
macrophages [13,14].  Among these stromal elements, the thymic epithelial cells 
are the most abundant cell types which forms a delicate 3D cellular network 
spanning throughout both the thymic cortex and the medulla.  The requirement for 
a 3D-supporting stroma appears to be unique to T cell development, as the in vitro 
development of other hematopoietic lineages, including B cells and NK cells, 
does not require a 3D structure [15]. 
The intrathymic development of T cells consists of several phases that require a 
dynamic relocation of developing lymphocytes within multiple architectural 
structures of this organ. T-cell progenitors originate in the bone marrow, enter the 
thymus and, through a series of defined and coordinated developmental stages, 
differentiate, undergo selection, and mature into functional T cells.  The steps in 
this process are regulated through a complex transcriptional network, specific 
receptor-ligand pair interactions, and sensitization to trophic factors, which 
mediate the homing, proliferation, survival, and differentiation of developing T 
cells.  
Following the entry into the thymus through the cortico-medullary junction, 
lymphoid progenitor cells begin their commitment toward the T-cell lineage.  The 
developmental pathway is traditionally divided into three subsequent steps, as 
defined by peculiar immunophenotypic patterns: the CD4
–
CD8
–
 double negative 
(DN) stage, the CD4
+
CD8
+
 double positive (DP) stage and the CD4
–
CD8
+
 or 
CD4
+
CD8
–
 single positive (SP) stage.  In mice, an immature single positive (ISP) 
CD8
+
CD4
–
 cell may be detected between the DN and DP stages (Figure 1).     
7 
 
 
Figure 1. Steps of the T-cell development 
 
The transition to the next stage in development depends on interactions with a 
complexity of thymic stromal cells and, in particular, the 3D configuration of 
thymus maximizes this interaction allowing intercellular cross-talk integral to the 
development of both T cells and TSCs [16-20].  In particular, signals from early 
CD4
–
CD8
–
 DN T-cell precursors and/or their immediate progeny provide the 
signals that promote the formation of the thymic cortex, while, later in ontogeny, 
the differentiation of thymic epithelial cells to a medullary phenotype and the 
subsequent formation of a medulla proper are clearly dependent on the presence 
of CD4
+
CD8
-
 and CD4
-
CD8
+
 SP selected thymocytes [18,21,22]. 
The DN stages transition requires the expression of different arrays of genes, as 
the induction of recombinase activating gene-1 (RAG-1) and RAG-2, the 
upregulation of pre-Tα (pTα) and the rearrangement of T-cell receptor (TCR) δ 
and γ.  These cells become competent to undergo β-selection and express the pre-
TCR complex on their surface and reach the DN3 stage [23].  After β-selection, 
the thymocytes, which have properly rearranged TCRβ chains, show a burst of 
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proliferation and a subsequent upregulation of CD8 and then CD4 and become DP 
cells.  Eventually, DP cells rearrange TCRα gene, leading to TCRα assembly into 
a TCR complex.  In the cortex, the DP thymocytes interact through their TCR 
with peptide-MHC complexes expressed by stromal cells, as cTECs and dendritic 
cells [24].  At this site, take place the positive selection, where ‘productive’ T 
cells react to foreign antigens, but not to self antigens [25].  Lately, positively 
selected DP thymocytes are ready to differentiate into SP cells, that is CD4
+
CD8
–
 
or CD4
–
CD8
+
 and relocate into the medulla.  At this site, newly generated SP 
thymocytes are further selected by the medullary stromal cells, including 
autoimmune regulator (AIRE)-expressing mTECs.  The cells that are reactive to 
tissue-specific self antigens are deleted, thus avoiding autoimmunity [25].  SP 
thymocytes egress from the thymus as recent thymic emigrants (RTE), naïve cells.  
These RTE cells are fully mature T cells that exert proper functional capabilities 
of cell-mediated immunity [26-28]. 
 
§1.1 T-cell development: focus on FOXN1 
The thymic microenvironment is composed primarily of an integrated 
meshwork of cortical and medullary TECs, required for promoting most stages of 
the thymocyte differentiation [17]. In particular, the epithelial cell-autonomous 
gene Foxn1 is required for thymic epithelial patterning and differentiation from 
the initial epithelial thymic anlage to a functional cTEC and mTEC meshwork 
during crosstalk with the lymphoid compartment.   
FOXN1 gene belongs to the forkhead gene family that comprises a diverse 
group of ‘winged-helix’ transcription factors that have been implicated in a 
variety of biochemical and cellular processes, such as development, metabolism, 
aging and cancer [29,30].   
Foxn1 gene is differentially expressed during the life span.  In particular, 
during the prenatal life the transcription factor plays a critical role in the 
appropriate development of several epithelia, such as that of liver, lung, intestine, 
kidney and urinary tract.  Postnatally, Foxn1 is mainly expressed in thymic 
epithelial cells, some keratinocyte populations and hair follicles, where it acts 
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through its molecular targets to regulate the balance between growth and 
differentiation [31-33].   
The development and maturation of TEC subsets during the thymus 
organogenesis occurs through two genetic stages [31,34], first stage being Foxn1-
independent and under the control of genes such as Hoxa3 [35] and Tbx1 [36], 
during which induction and outgrowth of the thymic epithelial anlage from the 
third pharyngeal pouch take place.  In the Foxn1-dependent step, precursor 
epithelial cells differentiate into mature and functional cTECs and mTECs from 
the same bipotential TEC progenitor [34,37-39].  Of note, Foxn1 is expressed in 
all TECs during embryogenesis, but not in all TECs of the adult thymus [40], 
indicating that the gene is strictly developmentally regulated.  Since Foxn1 
regulates the undifferentiated TECs, its expression in the adult thymus reveals the 
presence of TEC progenitors [41], which support TEC homeostasis in the adult 
thymus. 
As far as concerned FOXN1 function in the skin, its role, its target genes and 
the molecular mechanism of action still remain to be fully clarified. A detailed 
analysis of the Foxn1 expression in mouse skin has revealed a specific pattern of 
expression, suggesting its key role in the regulation of keratinocytes growth and 
differentiation [32].  
However, it is largely unknown whether the role of foxn1 in the thymus and 
skin is identical. One important difference is that, it has recently been 
demonstrated that Foxn1 is also involved in the 3D thymic micro-structure 
morphogenesis and maintenance [42] and, eventually, Foxn1 must be considered 
as a prime downstream mediator of agents or pathways also capable to induce 
thymic involution or rebound.   
Although FOXN1 has been long studied, most of the studies thus far available 
are restricted to fetal differentiation process, while its postnatal role in the mature 
thymus still remains to be fully elucidated. 
These data have been published as Review on Clinical and Developmental 
Immunology, for the manuscript see below. 
 
10 
 
 
11 
 
 
12 
 
 
 
13 
 
 
 
14 
 
 
 
15 
 
 
 
16 
 
 
 
17 
 
 
 
18 
 
 
 
19 
 
 
 
20 
 
 
 
21 
 
 
 
22 
 
§1.2 FOXN1 and human diseases 
Most of the pathogenic mechanisms underlying primary T-cell disorders are 
related to molecular alterations of genes selectively expressed in hematopoietic 
cells. However, since the differentiation process requires a crosstalk among 
thymocytes and thymic microenvironment, a severe T-cell defect may also be due 
to alteration of the stromal component of the thymus. The first example of a 
Severe Combined Immunodeficiencies (SCID) not primarily related to an 
abnormality intrinsic of the hematopoietic cell, but rather to a peculiar alteration 
of the thymic epithelial cell [43,44] is the Nude/SCID Syndrome (MIM 601705; 
Pignata Guarino Syndrome), due to the  absence of FOXN1 transcription factor, 
that results, both in mice and humans, in congenital athymia and hairlessness. The 
genetic alteration of the transcription factor, inherited as an autosomal recessive 
disorder, leads to a severe T-cell immunodeficiency, congenital alopecia of scalp, 
eyebrows and eyelashes. This phenotype, referred as Nude/SCID, was described 
for the first time in humans in 1996 in two sisters originating from a small 
community in the south Italy [43]. This phenotype is widely accepted as the 
human equivalent of the similar murine phenotype, reported for the first time by 
Flanagan in 1966 [45].   
The Nude/SCID immune deficiency is characterized by a severe blockage of 
the T-cell differentiation and absence of proliferative response to the common 
mitogens [43].  Naive T cells are lacking in the peripheral blood, as a consequence 
of the absence of a T-cell differentiation process. there is no curative therapeutic 
approach for Nude/SCID syndrome.  Bone marrow transplantation has been 
performed in one child with the Nude/SCID phenotype due to FOXN1 deficiency 
but without the production of the naïve T-cell pool and long lasting 
immunological reconstitution [46]. This would be expected given the absence of a 
functional thymus and to the necessary role of the FOXN1 transcription factor for 
a proper T-cell development. Nude/SCID phenotype is also characterized by nail 
abnormalities and variable abnormalities of the central nervous system, such as 
multiple-site neural tube defects or only the absence of the corpus callosum and 
cavum septi pellucidi and an enlargement of the interhemispheric fissure, have 
23 
 
been reported suggesting that FOXN1 may be implicated as a co-factor in the 
development of vital systems required for a proper fetus development [47].  This 
would explain the high mortality rate during the first trimester of pregnancy 
reported among consanguineous carriers of the mutation, which is not justified by 
the SCID per se due to the maternal protection until the third month after birth.   
These data have been published as Review on International Reviews of 
Immunology. 
24 
 
§1.3 New strategy to develop an in vitro thymic organoid  
In congenital immunological disorders and, in particular, in athymic disorders, 
a scaffold mimicking the 3D structure of primary lymphoid organs may be 
potentially used for the differentiation of hematopoietic cell precursors and, 
eventually, allows the re-setting of immunological response through functional or 
molecular manipulation of precursor cells.  An important feature of the thymic 
microenvironment is its 3D organization, consisting of an ordered architecture of 
TSCs, through which the developing thymocytes migrate and mature [48].  This 
3D configuration maximizes the interaction of developing thymocytes with the 
supporting stromal cells, allowing a proper intercellular cross-talk integral to the 
development of both T cells and TSCs [16].  
A remarkable number of similarities are shared between the epithelial and 
stromal cells of the thymus and keratinocytes and fibroblasts of the skin.  In 
particular, both thymic and skin epithelial cells selectively express the FOXN1 
transcription factor, which plays a critical role in differentiation and survival of 
these specialized cells [49-51].  By contrast, a major difference between thymus 
and skin is the architecture of each organ, in that the skin epithelial cells are 
mostly distributed along a basement membrane differently from epithelial cells of 
the thymus, which are organized in a 3D configuration. 
It has been recently documented that 3D tantalum-coated carbon matrix is able 
to support the development of functional T cells from hematopoietic precursor 
cells in the context of a heterogeneous multicellular system [52], even though the 
capability of the system to ensure a complete process, resulting in mature type T 
cells, is still under debate [53].   
The ex vivo reproduction of microenvironments of the native tissue through 
approaches based on the use of porous and biodegradable matrices has been 
proven useful to repair or replace tissues damaged at molecular or functional level 
[54].  This approach has been successful in achieving the regeneration of many 
tissues, such as skin [55], cornea [56], blood vessels [57] and in bone replacement 
process [58,59]. 
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Optimal scaffold materials should exert the properties of excellent 
biocompatibility, suitable microstructure, controllable biodegradability and 
suitable mechanical properties to sustain and facilitate a proper intercellular 
connection [60,61].  Scaffold surfaces need to be organized to allow optimal cell-
cell contact, growth, maintenance of morphology and viability over time to meet 
the demands of the specific application [62]. 
We verified the hypothesis whether cellular elements of the skin, spatially 
arranged in a 3D polycaprolactone (PCL) architecture, can support in the absence 
of thymic components the survival of HSCs and their differentiation into T 
lineage-committed cells.  
The 3D organization is unique to thymic epithelial cells, in that in other organs, 
epithelial cells are “polarized” and placed on a basal lamina, forming sheets of 
cells lining internal and external surface [42,63].  The peculiar 3D organization of 
TECs creates a proper microenvironment, which allows thymocytes migration and 
a tight lympho-stromal interaction [48,64].  Fetal thymic stromal cell monolayer 
cultures (TSMC) are not able to support T lymphopoiesis, thus indicating that the 
3D structure is required [63].   
Recently, a thymic organoid has been engineered by seeding tantalum-coated 
carbon matrix with thymic murine stroma [65]. This composite was able to 
generate mature functional T cells from bone marrow derived hematopoietic 
progenitor cells.  In our study, for tissue engineering a different material, as the 
PCL, has been chosen, since it is a biocompatible structure with a high surface 
area/volume ratio due to its high porosity, thus being an ideal scaffold (Figure 2).  
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Figure 2 Qualitative and quantitative investigation of PCL scaffold morphology.  Scanning 
electron micrographs of macropores (cross-section in the square) (A) and micropores (B).  (C) 
Cumulative distribution of pore surface and volume estimated by 2D-IA and MIP techniques, 
respectively.  APR: average pore radius. Scale bar: 20 and 300 µm. 
 
 In addition, the bimodal population of pores is strongly desired to assure an 
efficient nutrient transport and waste removal within the scaffold. In addition, cell 
growth and migration are also favoured thanks to a higher surface/volume ratio 
[66].  Our findings are in keeping with previous observations, which indicate that 
PCL scaffolds are suitable in guiding cell growth and in facilitating the synthesis 
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of extracellular matrix, thus leading to the formation of functional tissues and 
surrogate organs [67]. 
Since skin derived keratinocytes share several similarities with TECs, our data 
demonstrate that these cells, in the absence of thymic cellular elements, can 
replace TECs functionality in supporting the T-cell differentiation process.  
In particular, to reproduce in vitro the thymic microenvironment, previously 
expanded fibroblasts and keratinocytes were seeded together onto artificial 3D 
PCL scaffolds and each cell type was capable to interact with both the material 
and one to each other (Figure 3). A strong interaction of keratinocytes with 
fibroblasts occurred, resulting in skin cells occupancy of overlapping sites on the 
scaffold. This characteristic is most important for our system in that it ensures a 
stable interaction essential to reproduce an in vitro “organoid”.   
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Figure 3. Representative Scanning electron micrographs of keratinocytes and fibroblasts co-
coltured on the PCL scaffold.  The cells were fixed for 2 h and processed for SEM imaging.  
Each cell type was capable to interact with the material and one to each other.  The panels B, D 
and F show high magnification SEM images of the panels A, C and E, respectively. Scale bars: 
100 µm (A-E), 40 µm (B-C-F), 20 µm (D).  F:Fibroblast, K:Keratinocyte.  Original magnifications 
are as follows: panels A and E: X800; panel F: X1600; panel B and C: X 3000; panel D: X6000. 
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Moreover, to evaluate the importance of the keratinocytes and fibroblasts on 
CD34+ cells maintenance and differentiation, the cells harvested from the 
constructs were analyzed by flow cytometry during the 5 w of culture.  We 
demonstrate that the CD34+ cells decreased during the cultures. In the 
keratinocytes/fibroblasts/PCL scaffold these cells were more represented during 
the culture and persisted longer than in the control cultures.  Moreover, evaluating 
the behaviour of CD34+ HSCs compared with that of CD45+ in the 
keratinocytes/fibroblasts/PCL scaffold, we showed that, differently from HSCs, 
CD45+ cells persisted in the culture at least for 5 w, thus suggesting that in the 
presence of the multicellular biocomposite, rearranged in a 3D configuration, stem 
cells undergo to a differentiation process (Figure 4).  
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Figure 4. Keratinocytes and fibroblasts seeded on the 3D scaffold support the HSCs  
survival. Representative flow cytometry data for CD34 (gated on CD45+ cells) cell staining (A) 
and quantification of CD34+ cells cultured on PCL scaffold/keratinocytes/fibroblasts in 
comparison to the control systems (B). Measurements were made at 0, 1, 2, 3, and 4 w of culture.  
Error bars represent the SD of three independent experiments.  (C) Behaviour of CD34+ HSCs and 
CD45+ cells in the PCL scaffold/keratinocytes/fibroblasts system. Measurements were made at 0, 
1, 2, 3, 4, and 5 w of culture.  Error bars represent the SD of three independent experiments.   
 
We observed that in the multicellular biocomposite, CD7+ cells were de novo 
generated by the 3rd w of culture.  Subsequently, at the 5th w of culture, these 
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cells also expressed the CD1a marker.  Furthermore, CD4 immature single 
positive cells, not yet expressing CD3 and CD8 markers, were detected during the 
culture (Figure 5).   
 
Figure 5. Keratinocytes and fibroblasts seeded on the 3D scaffold support the HSCs 
differentiation into T-lineage committed cells.  (A-B-C-D) Representative flow cytometry data 
for CD45, CD7, CD1a, CD3, CD4, CD8 cells staining of the cells cultured on PCL 
scaffold/keratinocytes/fibroblasts in comparison to the control systems at different time points. 
Measurements were made at 0, 1, 2, 3, 4, and 5 w of culture.  Results shown are representative of 
at least three independent experiments. 
 
These findings are in keeping with the observation that thymic precursors, at 
the earliest stages of T-cell development, first acquire the CD7 marker [68].  
However, these cells along with T cells can also give rise to NK and myeloid 
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precursors [69].  The transition to CD7
+
CD1a
+
 stage is considered peculiar of a T-
cell commitment.  At the next developmental stage, the pre-T cells express CD4, 
but not yet CD3 and CD8, and are thought to be CD4 immature single positive 
(ISP) cells.  Later in the differentiation process, the cells express CD4 and CD8 
and are referred to double positive cells, that subsequently mature in single 
positive CD4 or CD8 cells [70]. 
In our study, through the evaluation of the expression patterns of genes 
selectively expressed in the hematopoietic component of the multicellular 
biocomposite, we confirmed that an in vitro de novo generation of cells 
committed toward the T-cell lineage occurred.  Of note, TAL1 was down-
regulated and Spi-B up-regulated in the cell suspension, consistently with the loss 
of the multilineage differentiative potential.  Moreover, PTCRA and RAG2 
expression was detectable at the 3rd w, indicative of a recombinant activity 
(Figure 6).  These molecular events were not observed in the control systems and 
are consistent with the immunophenotypic data, supporting an ongoing T-cell 
differentiation process.   
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Figure 6. Expression patterns of selected T-lineage specific genes during the HSCs 
differentiation in the multicellular biocomposite.  Real-time PCR evaluation of Ikaros (A), 
TAL1 (B), Spi-B (C), PTCRA (D)  and RAG2 (E) expression in suspensions of hematopoietic 
cells grown on PCL scaffold/keratinocytes/fibroblasts or control systems. Gene expression was 
normalized to the expression of β-actin.  The values indicate the relative mRNA expression.  Data 
represent the mean ± SD from two independent experiments. 
 
It is known that at early stages of this process, the cells initially express TAL1, 
which sustains the lineage plasticity.  These cells, therefore, retain the potential to 
become other hematopoietic cell types [71,72].  The down-regulation of this 
molecule is strongly correlated with the activation of T-cell gene expression 
program, whose hallmark is the expression of Spi-B and the genes involved in the 
TCR rearrangement, such as RAG1/2 and PTCRA [73].  Eventually, the cells are 
committed to a T-cell fate [74]. 
Our data, indicating that keratynocytes are able to sustain the process, are not 
surprising, since epithelial and stromal cells of the thymus and skin derived 
keratinocytes share a remarkable number of similarities.  Of note, keratinocytes 
express FOXN1, a developmentally regulated transcription factor, selectively 
expressed in epithelial cells of the thymus and skin, where it plays a critical role in 
cell differentiation and survival resulting in T lymphopoiesis [33,49].  FOXN1 is 
also expressed in all TECs during initial thymus organogenesis and is required for 
the initial phase of their differentiation [31,37,75].  Genetic alterations of FOXN1 
lead to athymia[45,76] and result in humans in a Severe Combined 
Immunodeficiency phenotype associated with skin annexa abnormalities, referred 
as the human equivalent of the mice Nude/SCID syndrome [43,46,77]. This 
athymic condition is more severe than that observed in the other athymic 
condition represented by the DiGeorge syndrome, which is only characterized by 
a moderate reduction of T cells, which are under several aspects functional [78].  
DiGeorge patients, differently from Nude/SCID ones, have circulating naïve cells, 
thus suggesting that ectopic thymus anlage or additional structures may contribute 
to lymphopoiesis.  Our data lead us to argue that skin and, in particular, 
keratinocytes may play such a role thanks to the FOXN1 expression. Of note, 
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prenatal alteration of the FOXN1 gene in humans prevents the development of the 
T-cell compartment, in particular leading to a complete blockage of the CD4+ T-
cell lineage maturation [79]. 
In conclusion, our results indicate that, in a multicellular biocomposite 
containing skin derived elements in the absence of thymic stroma, HSCs do start 
differentiating and that the process is also directed toward a T-cell lineage 
commitment in the presence of IL-7, IL-15 and Flt3-Ligand.  However, the 
maturation process does not lead to the production of fully mature single positive 
T cells.  This suggests that additional factors or molecular manipulations should 
be used to reproduce a thymic epithelial cell-like surrogate environment.  The in 
vitro re-build of an environment capable to reproduce tissue features of primary 
lymphoid organs is of valuable help for future therapeutic strategies of patients 
affected with congenital hematologic and immunologic disorders. 
 
§1.4 Conclusive remarks 
Despite an extensive knowledge about the thymus role to foster T-cell 
development is available, some still unexplained evidence in human athymic 
conditions suggests that in depth information of this process is still to be achieved 
and, in particular, the involvement of different non lymphoid tissues in T-cell 
ontogeny.  
The simultaneous occurrence of severe functional T-cell immunodeficiency 
and skin abnormalities associated to FOXN1 alterations indicates that the factor 
exerts a critical role in the development and homeostasis of these epithelia and 
suggests shared functions of the gene in both thymus and skin epithelium.   
Despite the significant progress, the detailed mechanism by which FOXN1 
controls the T-cell differentiation process through intercellular cross-talk still 
remains to be clarified.  
Additional knowledge in this field would be very helpful in conclusively 
defining the role of FONX1 in the biological process, in clarifying the intimate 
mechanisms of FOXN1 action and in the development of novel therapeutic 
strategies for congenital disorders of immune system. 
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CHAPTER II 
“Impaired regulation of the immune system” 
 
Within the thymus, developing thymocytes undergo positive and negative 
selection, resulting in mature T cells that are able to successfully recognize a wide 
range of foreign antigens and, at the same time, able to ignore self-antigens. 
Potentially, autoreactive naive T cells, which succeed in reaching the periphery, 
are functionally suppressed by several mechanisms, in a process known as 
peripheral tolerance. Breakdown of the central or peripheral tolerance leads to the 
development of destructive autoimmune reactions and, paradoxically, in a few 
circumstances also to immunodeficiency, as seen in experimental conditions 
regarding alteration of the transcription factor Autoimmune Regulator (AIRE) 
protein or FOXP3. Recent evidence suggests that systemic autoimmunity and 
immunodeficiency can be strictly interconnected. In immunodeficiencies, the 
decreased or abolished capacity of the immune system to clear infections causes a 
continuous immunological stimulation and activation, which represents one of the 
potential mechanisms that eventually leads to autoimmunity. Dysregulation of 
immunoregulatory factors combined to multiple genetic variations is responsible 
for systemic autoimmunity. In a few cases, along with a predominant autoimmune 
phenotype, an increased susceptibility to infections is also present [80]. Several 
studies have reported evidence indicating that autoimmune phenomena occur in 
patients affected with primary immunodeficiencies, and have focused on the 
molecular and cellular mechanisms underlying these conditions, in order to 
elucidate the link between autoimmunity and immunodeficiency. On the other 
hand, studies on genetic autoimmune disorders are also extremely useful for our 
understanding of the pathophysiology of the intimate mechanisms that lead 
autoreactive clones to escape clonal deletion [81,82]. Currently, unique models, 
which help unravel many aspects of the development, homeostasis and regulatory 
properties of the immune system, are the monogenic autoimmune disorders and, 
in particular, autoimmune polyendocrinopathy candidiasis ectodermal dystrophy 
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(APECED), immunodysregulation, polyendocrinopathy and enteropathy X-linked 
(IPEX), autoimmune lymphoproliferative syndrome and IL-2 receptor α-chain 
(IL-2RA, CD25) deficiency. Impairment of central or peripheral tolerance, which 
normally prevents the survival, expansion and activation of autoreactive T cells, 
thus protecting from autoimmune diseases, is the main pathogenetic mechanism 
responsible for these conditions.  
 
§2.1 Abnormalities of the central and peripheral tolerance 
Self–nonself discrimination plays a key role in inducing a productive immunity 
and in preventing autoimmune reactions. Altering this balance will result in 
immunodeficiency or autoimmunity. In this context, positive and negative 
selections are crucial for the creation of a T-cell repertoire able to respond to a 
huge number of foreign antigens, preserving, at the same time, the tolerance to 
self-antigens expressed in the various tissues [83]. 
Tolerance represents a state of immunologic nonresponsiveness in the presence 
of a particular antigen. The immune system is able to discriminate between self- 
and nonself-antigens. This property is fundamental to induce a productive 
immunity and to prevent autoimmune reactions. Altering this balance will result 
in immunodeficiency or autoimmunity. Immune tolerance to self-antigens is 
acquired through two main processes: central and peripheral tolerance [83]. 
Central tolerance takes place within the thymus through the negative selection 
process, which occurs subsequently to the positive one. Eventually, the tolerance 
to self-antigens expressed in various tissues is acquired [83]. 
Within the thymic medulla, thymic medullary epithelial cells (mTECs) and 
medullary dendritic cells (mDCs) play a central role in the establishment of self-
tolerance through the negative selection process [84].  Both cellular types, 
expressing the costimulatory molecules, CD40, CD80, CD86 and MHC class II, 
are able to favor an efficient thymocyte deletion. mTECs express a thousand 
genes, the so-called ‘promiscuous gene expression’, including tissue-specific self-
antigens (TSAs), normally present only in specialized peripheral organs [85]. This 
high expression by mTECs of genes encoding TSAs is driven by transcription 
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factor autoimmune regulator (AIRE) [86-88]. These MHC-restricted self-antigens 
are presented by mTECs to developing T cells. Thymocytes that recognize self-
antigens with high affinity/avidity are deleted [89].  Mutations of AIRE result in 
autoimmune polyendocrinopathy candidiasis ectodermal dystrophy, a rare 
autosomal recessive disease (OMIM 240300), which is the paradigm of a 
genetically determined failure of central tolerance and autoimmunity [90,91]. 
Some of the thymocytes, which bind self-MHC–peptide complexes with high 
affinity, express Foxp3, and through a yet unknown mechanism escape negative 
selection and differentiate into Tregs, which play an important role in the 
peripheral tolerance suppressing autoreactive T cells in the periphery [92,93]. 
Triggering the costimulatory molecules and the subsequent activation of Fas 
signaling pathway represents the commonly accepted mechanism to explain the 
deletion of self-reactive thymocytes within the thymus [94]. 
Fas-Fas Ligand interactions are implicated in the elimination of self-reactive T 
cells by a process known as restimulation induced cell death. The role of Fas is, 
thus, restricted to the elimination of T cells specific for autoantigens and chronic 
pathogens. This process has a crucial role in maintaining self-tolerance in T cells 
that have escaped central thymic tolerance. T-cell receptor (TCR) engagement of 
activated T cells results in FasL gene upregulation and secretion [95] and in 
translocation of Fas to lipid rafts providing a critical and physiologically 
significant signal that sensitizes T cells to Fas-mediated apoptosis. FasL is 
constitutively expressed on cells of immune privileged organs, such as brain, 
anterior chamber of eyes, and testes. In consequence, FasL protects these 
privileged sites from the action of immune system cells, as an additional 
regulatory mechanism of self-tolerance. On the contrary, FasL expression is 
usually transient on activated T cells. Many signaling pathways and transcription 
factors mediates inducible FasL expression T cells. Fas is also implicated in B cell 
function regulating autoantibody production and antigen presenting cell function. 
In particular Fas mediates peripheral B cell tolerance.  
Mutations affecting Fas and FasL confer potent susceptibility to autoimmune 
diseases, such as Autoimmune lymphoproliferative syndrome (ALPS).   
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§2.1.1 Altered central tolerance and autoimmune disease 
The paradigm of a genetically determined failure of central tolerance and 
autoimmunty is the APECED, a rare autosomal recessive disease due to the 
mutation of the AIRE gene.  Patients with APECED have a highly variable pattern 
of destructive autoimmune reactions toward different endocrine and nonendocrine 
organs mainly involving parathyroid glands, adrenal cortex, gonads, pancreatic 
beta cells, gastric parietal cells, and thyroid gland. Moreover, ectodermal 
abnormalities are frequently present. The classical clinical diagnosis is primarily 
based on the presence of two of the three most common clinical features: chronic 
mucocutaneous candidiasis (CMC), chronic hypoparathyroidism  (CH), and 
Addison disease (AD) [96]. The presence of only one component is sufficient for 
the diagnosis if a sibling is affected [97].  However, although APECED is a 
monogenic disorder, it is characterized by a wide variability of the clinical 
expression, thus implying a further role for disease-modifying genes and 
environmental factors in the pathogenesis.  
We also described a patient in which adrenal failure was the presenting feature of 
primary  primary antiphospholipid syndrome (APS). 
These data have been published as Review on International Reviews of 
Immunology and Expert Reviews of Immunology, and as Article on Italian 
Journal of Pediatrics, for the manuscripts see below. 
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§2.1.2 Altered peripheral tolerance and autoimmune disease 
The paradigm of abnormal peripheral tolerance is ALPS, a disorder 
characterized by nonmalignant lymphoproliferation, increased risk of lymphoma, 
and autoimmunity often manifesting as multilineage cytopenias [98,99] The most 
common genetic alterations are heterozygous germline mutations in the gene 
encoding the TNF receptor family member Fas (CD 95, Apo-1) [100-102], 
somatic Fas mutations and mutations in the genes encoding Fas-ligand (FASLG), 
caspase 10 (CASP10) and caspase 8 (CASP8), and NRAS and KRAS [103].  
However, in a large group of ALPS patients the molecular defect still remains to 
be identified. 
Alterations of homeostatic mechanism resulting in an abnormal lymphocyte 
accumulation, autoimmunity or lymphoid malignancies, have now emerged as a 
novel pathogenic mechanism underlying intense poly-reactive auto-reactions 
[104,105]. Recent evidence indicates that, in a few cases, Clustering of 
Autoimmune Disorders (CAD) may represent unique model of monogenic 
autoimmune disorder or a sign of congenital immunodeficiencies [106-108]. CAD 
has been defined by the presence of at least three distinct organ-specific or 
systemic immune disorders in the same individual [109]. We reported on a 
functional impairment of cell death, induced through Fas triggering, in the 60% of 
a cohort of patients affected with CAD, thus suggesting some overlap with ALPS 
[104,110]. Only in 1 patient the functional alteration was associated with Fas gene 
(TNFRSF6) mutation. Our study highlights the importance to evaluate Fas-
induced cell survival in the clinical approach to patients with CAD even though 
the exact role of Fas-induced cell death abnormalities in the pathogenesis of CAD 
remains to be fully elucidated. 
The results of this study were published on Italian Journal of Pediatrics, for 
the manuscript see below. 
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§ 2.1.3 SCID-like phenotype associated with autoimmunity 
Interestingly, evidence is emerging that, unlike total immunodeficiencies, 
partial T-cell immunodeficiencies are more frequently associated with 
hyperimmune dysregulation with a frank autoimmune phenotype [111].  Even 
more interesting the observation that the loss of function or gain of function 
alterations in the immune system functionality may arise from abnormalities of the 
same multiple genes, that in some cases lead to total and in other to partial 
deficiencies.  This would imply that the hyperimmune dysregulation is not related 
to selected genes alterations, but rather to the partial T-cell immunodeficiency 
itself [111].   
We reported a patient with a clinical phenotype resulting in a typical 
lymphocytopenic T
-
B
+
NK
+
 SCID.  A similar phenotype is generally due to an 
impairment of the T-cell differentiation process resulting in a severe reduction in 
peripheral T-cell pool size associated with molecular alterations of genes 
implicated in T-cell ontogeny and functionality [112-114].   
In conclusion, this SCID-like patient was characterized by a severe T-cell 
activation deficiency, in whose serum an inhibitory factor, precipitated in the 
purified Ig fraction and able to potently inhibit control cells proliferation, was 
identified.  So far, an autoreactive anti-lymphocyte antibody able to induce a SCID 
phenocopy has never been described.  Notably recent studies have identified 
immunodeficiencies associated with the presence of autoantibody against several 
cytokines such as interferon (IFN)-γ  interleukin (IL)-17, IL-22.  
The results of this study were published on Journal of Investigational 
Allergology & Clinical Immunology, for the manuscript see below. 
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§ 2.2 T-helper 1 / T-helper 2 imbalance 
The identification of distinct CD4+ T helper cells (Th1 and Th2) exerting 
peculiar functions and differing on the basis of the production of a unique 
cytokine profile greatly contributed to our understanding of the intimate 
mechanism implicated in the different type of host immunity. Th1 cells 
produce interferon (IFN)-γ and interleukin (IL)-2 and, predominantly, 
promote cell mediate immune responses, whereas Th2 cells that produce 
IL-4, IL-5 and IL-13 provide help for some B cell responses as IgG1 and 
IgE production [115,116]. Overall, an appropriate immune response mostly 
relies on a well orchestrated Th1/Th2 dichotomy, whose hallmark is based 
on the capability of the individual subset to work in an autocrine fashion 
leading to amplify its own cell development and to cross-regulate the other 
subset development and activity [117,118].  
It has been hypothesized that Th1/Th2 imbalance cause elevated IgE 
serum levels. Moreover, the susceptibility to infections by certain pathogens 
is associated with low levels of IFN-γ [119]. Thus, alteration of Th1/Th2 
homeostasis, also involving further regulatory T cells as Th17, may lead to 
diseases in humans [117,120]. A Th1 response is implicated under ordinary 
circumstances in resistance to several intracellular pathogens, but an 
excessive Th1 response is associated with different autoimmune diseases, 
as rheumatoid arthritis [121,122], type I diabetes [123] or multiple sclerosis 
[124]. On the contrary, a Th2 dominated response, usually involved in the 
response to extracellular pathogens as parasitic or helminths, is associated 
with allergic disorders and the progression of chronic infections as AIDS 
[125]. The dimeric cytokine IL-12, produced by B cells and macrophages, 
plays a pivotal role for the induction of a Th1 response [126].  Its cloned 
receptor consists of two subunits, IL-12Rb1 and b2, both required for high 
affinity binding to IL-12 and full cytokine responsiveness [127]. The 
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receptor is up-regulated during T-cell activation and IL-12Rb2 transcript is 
selectively expressed in Th1 cells following IL-12 stimulation, while IL-
12Rb1 is constitutively expressed in resting cells [128]. The transducing 
element of the receptor is the IL-12Rb2 chain that functionally interacts 
with members of the family of STAT, and in particular STAT4. This 
transcription factor is promptly phosphorylated on tyrosine residues upon 
receptor triggering [129]. Th1 cells develop in the presence of IL- 12 and 
STAT4 signaling and secrete mainly IFN-γ [130].  
 
§ 2.2.1 Hyper IgE and IL12R deficiency 
Hyper IgE Syndrome (HIES) is a very rare primary immunodeficiency, 
characterized by the high serum levels of IgE (>2000 IU/ml), recurring 
staphylococcal skin abscesses and pneumonia with pneumatocele formation.  
Most cases are sporadic, but both autosomal dominant forms of HIES and 
autosomal recessive forms have been described. Skeletal symptoms such as 
hyperextensibility of joints, scoliosis, osteoporosis, and retained primary teeth are 
associated with the autosomal dominant form.  An autosomal recessive disease 
characterized by severe recurrent viral infections, extreme eosinophilia and 
devastating neurological complications that are often fatal in childhood, has been 
described.  Patients with the autosomal recessive form appear to be prone to 
developing autoimmune diseases.  HIES usually presents very early in life.  
Clinical diagnosis has been based on a profile of immunologic and non-
immunologic features leading to a composite score.  Specific mutations have not 
been identified in these patients [131].   
It has been hypothesized that elevated serum levels of IgE are associated with a 
Th1/Th2 imbalance.   
We investigated, at a functional level, whether an impaired induction of Th1 
response occurred in patients with elevated IgE serum levels and whether such 
abnormalities were correlated with alterations of the IL-12 receptor signaling 
apparatus.  In particular, the activation of STAT4 molecule, which follows IL-12R 
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triggering, the analysis of gene transcription and membrane assembly of the 
receptor itself were investigated in allergic children divided on the basis of the 
amount of serum IgE.  We provided evidence of altered IL-12/IL-12R signaling in 
patients with very high IgE level, suggestive of an impaired Th1 induction.   
It is noteworthy that all the abnormalities herein described were observed only 
in patients with IgE levels higher than 2000 kU/l, which represent only a minority 
of patients, and not in atopic patients with an ordinary increase of IgE levels.  The 
cut off of 2000 kU/l is generally assumed as a presumptive sign to select patients 
at risk of being affected by HIES.  However, this syndrome was excluded in our 
patients by the absence of the typical clinical and immunological features [131].  
In particular, no recurrent skin infections, facial, skeletal and dentition anomalies 
were observed.   
Additionally, we described a child with recurrent bronchopneumonia 
associated with very high serum IgE levels, who exhibited a profound impairment 
of the Th1 generation associated with a variation in the exon 5 of the IL-12R β1 
gene (R156H) that exerts a summatory effect, as a genetic cofactor, along with an 
additional and still unidentified molecular alteration of the IL-12R pathway. Thus, 
in children with severe and recurrent infection, the functional and/or genetic 
alterations of the molecular mechanisms governing Th1/Th2 homeostasis might 
be responsible for an atypical immunodeficiency and, therefore, should be 
investigated in these patients  
The results of these studies were published as Article on Cellular Immunology 
and Italian Journal of Pediatrics.  See below for the papers. 
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§2.3 Conclusive remarks 
Recent evidence indicates that systemic autoimmunity and immunodeficiency 
can be strictly linked. Molecular mechanisms involved in central tolerance, along 
with those in peripheral tolerance, play a crucial role in the establishment and 
maintenance of immune self-tolerance, preventing autoimmunity and promoting 
the proper function of immune system. The discovery of genetic diseases caused 
by alterations of genes implicated in the tolerance mechanisms enormously 
contributed to our understanding of the molecular basis of human autoimmune 
disorders, generally and appropriately considered as multifactorial diseases.  
Moreover, a better understanding of the molecular mechanisms governing 
Th1/Th2 homeostasis may help ameliorate the overall management of the patients 
[132].   
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CHAPTER III 
“Alteration of immune system genes: cancer predisposition 
and neurodegeneration” 
 
The immune system has the greatest potential for the specific destruction of 
tumors with no toxicity to normal tissue and for long-term memory that can 
prevent cancer recurrence. The last 30 years of immuno-oncology research have 
provided solid evidence that tumours are recognized by the immune system and 
their development can be stopped or controlled long term through a process 
known as immune surveillance [133,134].  
In many cancers, however, malignant progression is accompanied by profound 
immune suppression that interferes with an effective antitumour response and 
tumour elimination [135].  It has become clear that the suppression comes from 
the ability of tumours to subvert normal immune regulation to their advantage. 
The tumour microenvironment can prevent the expansion of tumour antigen-
specific helper and cytotoxic T cells and, instead, promote the production of pro-
inflammatory cytokines and other factors, leading to the accumulation of 
suppressive cell populations that inhibit instead of promote immunity.  
 A strong predisposition for cancer development has been reported for some 
types of PIDs [6,7], such as ataxia-telangiectasia (AT), common variable 
immunodeficiency (CVID), Wiskott-Aldrich Syndrome (WAS), SCID, selective 
IgA deficiency, DNA repair deficiencies and Hyper IgM Syndromes.  The 
predisposition to cancer could be due to immunodeficiency itself, as tumor 
immune surveillance becomes impaired and infections by potentially oncogenic 
viruses are less likely to be dealt with effectively [136].  The main type of 
malignancy in PIDs is non Hodgkin lymphoma, which account with a frequency 
of 60 %, followed by Hodgkin lymphoma (23%) and leukemia (6%) [8].  All 
these types of malignancies develop more frequently in extranodal site, 
particularly in the central nervous system and gastrointestinal tract, and derive 
from malignant B cell proliferation [137].  However, the type of malignancy 
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depends on the specific PID, the age and the infective clinical history of the 
patients.  The genetic defect, underlying the immunodeficiency, may play a direct 
role in cancer pathogenesis either facilitating chronic infection, especially with 
oncogenic viruses such as Epstein Barr virus (EBV), or through genetic mutations 
in DNA double-strand breaks repair systems, which lead to accumulation of 
mutations that promote tumorogenesis [9]. 
In SCID due to mutations of genes involved in VDJ recombination, the genetic 
defect plays a direct role in the carcinogenesis.  These genes, in fact, encode 
proteins, such as Artemis and DNA ligase IV, involved in DNA double-strand 
breaks repair.  Impairment of this process lead to accumulation of gene mutations, 
worsened by radiosensitivity, which accelerate the malignant transformation of 
lymphocytes [138-140].  The same pathogenetic mechanisms can be observed in 
Atassia-Teleangectasia.  AT represent the primary immunodeficiency with the 
highest risk of malignancy [141].  ATM who is a member of the phosphatidyl 
inositol kinase molecule family, normally acts as a sensor of double-stranded 
DNA breakage.  In this context the predisposition to leukemia is connected to 
excessive production of translocations [7]. 
Hyper-IgM syndromes are caused by mutations in the genes encoding for the 
CD40/CD40L interaction pathway leading to defects in the class switch 
recombination.   X-linked hyper-IgM syndrome is associated with a highest risk to 
develop carcinomas of the liver, pancreas, biliary tract and associated 
neuroectodermal endocrine cells [142].  The chronic inflammatory stimulation 
due to defective clearance of cryptosporidia plays an important role in the 
carcinogenesis also in these syndromes in which carcinoma are often preceded by 
chronich epatitis and cholecystitis [143].   
The role of γc, IL-7R and JAK3 in tumor development further cement the 
relation between immunity and cancer even though in SCIDs associated with 
mutations in these genes cannot be observed an increased cancer susceptibility.   
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§3.1 The role of γc in endocrine system and cancerogenesis  
IL-2RG encodes the common cytokine γc of the IL-2 receptor.  The c gene, 
localized to chromosome Xq13, encodes a transmembrane protein which is a 
transducing element shared by the cytokine receptor superfamily, including IL-2, 
IL-4, IL-7, IL-9, IL-15 and IL-21.  [144,145].  Mutations in this gene are 
responsible for the X-linked Severe Combined Immunodeficiency (X-SCID), 
characterized by the complete absence of both T and NK lymphocytes, whereas B 
cell number is normal.  
The receptors containing γc exert prominent mitogenic effects and play an 
important role in several immunological functions and in supporting cell survival.  
The γc is involved also in growth hormone receptor (GH-R) signaling.  The 
impairment of various GH induced events in patients affected with severe 
combined immunodeficiencies due to γc defects suggests a potential functional 
interaction between GH-R pathways and γc, indicating a further link between 
endocrine and immune system with potential implication of the molecule in the 
cell cycle progression and control. Moreover, evidence indicates that the GH/IGF-
I axis has a role in the development of cancer through the regulation of cell 
proliferation, differentiation and apoptosis [146].  Even though IGF-I is mitogenic 
per se and exerts an important antiapoptotic effect the GH-R signaling apparatus 
also involves potent mitogenic molecules such as γc and signal transducers and 
activators of transcription (STAT) that play a role in the cell proliferation and, in 
general, in cell homeostasis [147-149]. Furthermore, as been shown that both GH 
induced and spontaneous cell cycle progression and cell growth are strongly 
dependent on the amount of γc expression. 
Of note, STATs play important roles in oncogenesis by up-regulation of genes 
encoding apoptosis inhibitors and cell cycle regulators, namely oncogenes, such 
as Bcl-xL, Mcl-1, cyclins D1/D2, and c-Myc. It has been also documented a 
constitutive activation of STAT3 or STAT5 in tumor cells resistant to 
chemotherapeutic agents, that exert their effect on cell apoptosis machinery.  
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These data have been published on Cellular Immunology, Current Signal 
Transduction Therapy and American Journal of Medical Genetics, for the 
manuscripts see below. 
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§ 3.1.1 Potential oncogenic role of the γc 
 
§ 3.1.1.1 The γc provides spontaneous or induced cell proliferation 
The intrinsic property of c in cell cycle progression has been long debated.  In 
fact, although gene therapy trials have been proved as a beneficial alternative 
approach to cure X-SCID patients carrying mutations of c, a malignant 
lymphoproliferation occurred in 5 out of 20 patients enrolled into the two different 
trials [150,151], not observed in gene therapy trials for SCID due to ADA 
deficiency [152].  To explain these adverse events, studies were conducted to 
define whether the retroviral insertional mutagenesis could have played a role.  In 
4 cases an aberrant transcription and expression of LMO2 was clearly 
documented [153].  Even though the other patients may have the vector 
integration near LMO2 or other oncogenes [153], it is also conceivable that the 
transgene could have a role per se in cell cycle progression.  Of note, development 
of leukemia, similar to other cancers, requires multiple genetic changes caused by 
a diverse group of genes that inhibit apoptosis and/or provide growth advantage to 
the leukemic cells [154].  In keeping with this hypothesis, overexpression of c 
transduced through a lentiviral vector into stem cells in murine model of X-SCID 
led to T-cell lymphomas and thymic hyperplasia in a third of the cases.  
Intriguingly, no common integration site was found between the mice, which 
developed T-cell lymphomas [155].  In these mice, differently from humans 
treated with gene therapy for X-SCID, the expression levels of the protein was 
elevated, thus implying that the amount of the protein may be crucial for the c 
control of cell cycle [156].  These results suggest that insertional mutagenesis may 
not be the only cause of laeukemogenesis and that the expression levels of c 
could influence the cell cycle progression directly or its effect being mediated by 
cytokines triggers.  
It has been documented that c receptors activity enhances leukemogenesis 
[157].  To define an intrinsic mitogenic property of c dependent on the amount of 
the protein, we used in vitro cellular models containing different amounts of c.  
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In particular, EBV-transformed B-cells (BCLs) from normal subjects, cells 
transduced with lipid vector containing nontargeting short interfering RNA 
(siRNA), BCLs transduced with siRNA to knockdown c expression and BCLs 
from X-SCID patients were used.  Our results indicate that silencing of c induces 
a substantial decrease of protein amount in BCLs, which allowed us to 
demonstrate a direct involvement of c in self-sufficient growth of BCLs in a 
concentration dependent manner.  We, also, found that the amount of 
constitutively activated JAK3 parallels the extent of c expression.  This finding is 
intriguing, in that constitutively active or hyperactive JAK proteins have crucial 
roles in hematopoietic malignancies, by promoting oncogenic transformation 
[157].  In particular, JAK overexpression can be considered as one of the main 
biologic events leading to the constitutive activation of the JAK/STAT pathway 
that contributes to oncogenesis [158].  In lymphoid cells, the involvement of the 
JAK/STAT pathway in several cellular processes, such as proliferation and 
protection from apoptosis, has also been well documented [159,160].   
We found that c silencing also inhibits GH-induced cell proliferation.  In this 
context, it is known that the activation of JAKs and STATs represents a prominent 
biochemical event during GH-dependent proliferation of lymphoid cell lines [161-
165] and STAT5 is considered a transforming agent in lymphoma and other cell 
types [166], therefore we found that the reduction of c amount also inhibits 
STAT5 activation and its subsequent nuclear translocation, which follows GHR 
perturbation.  Of note, it should be mentioned that experimental studies document 
a role for GH in the initiation and/or promotion of tumorigenesis, raising the 
possibility that patients treated with GH might be at increased risk of cancer 
[167].  Moreover, a putative role of GH as a cofactor in tumor growth is plausible, 
since several carcinomas express GHR [168].  In animal models, GH increase the 
incidence of leukemia and solid tumors, and in humans, at supraphysiological 
doses, it can promote lymphoproliferative events [169].   
In conclusion, our data demonstrate a direct relationship between the amount of 
c expression and its role in cell cycle progression.  These data add new evidence 
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for a possible intrinsic mitogenic role of c related to its cellular amount.  This 
biologic effect could be direct, thus related to the molecule per se, or indirect and 
mediated by the participation to cytokine-receptors signaling.  Therefore, since 
results of gene therapy trials for X-SCID have been very promising, to achieve 
safer results, the modulation of the transgene expression could help reduce the 
risk of undesirable events.   
These data have been published as Article on The Journal of Immunology, for 
the manuscript see below. 
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§ 3.1.1.2 Role of  γc on spontaneous cell cycle progression in human 
malignant cell-lines 
Cell cycle progression is a highly organized and regulated process that controls 
cell proliferation [170].  Cytokines that signal through receptors sharing the c 
lead to transition into the cell cycle and thus proliferation [171].  The entry of 
cells into the cell cycle is controlled by an ordered expression/activation of cyclins 
[172].  IL-2R through c appears to activate a variety of downstream signaling 
pathways that converge on the regulation of Bcl-2 [173], including PI3K and 
MAPK activation [174] and transcription of the c-myc gene [173].  In turn, c-myc 
cooperates with STAT5 to induce the expression of cyclin D and to promote 
proliferation [175-177].  It is clear that alterations in Bcl-2 family members levels 
exert potent effects on cellular survival and, namely, Bcl-2 overexpression can be 
tumorigenic [178].  Moreover, c is required for a wide range of signaling inputs 
that induce cell proliferation through cyclin D3 expression [179]. 
To determine whether c deficiency had an effect on cell survival we examined 
BCLs from healthy donors and X-SCID patients.  Our results first indicate that in 
the absence of c expression, BCLs die at a higher extent than control cells. This 
phenomenon is not related to abnormalities of regulatory mechanisms of 
apoptosis, in that, in non-stimulated cells, the absence of cc does not induce an 
increase of the activated form of caspase-3 that represents the central executioner 
molecule in the development of programmed cell death process [180].  . 
Programmed cell death is mainly mediated by activation of several caspases 
These molecules exist as pro-forms that are activated by cleavage by the upstream 
caspase in the cascade [180].  Caspase-independent cell death has been attributed 
to mitochondrial damage [181], which can be regulated by Bcl-2 family members 
[182,183].  The c-dependent cytokines promote cell survival by up-regulating the 
antiapoptotic factor Bcl-2 [184] and Bcl-XL [185].  In keeping with this, in c-
deﬁcient cells, the expression of Bcl-2 and Bcl-XL was greatly decreased as 
compared with the control.  These findings indicate that c is required for cell 
survival and is dispensable for Fas induced cell death.  Evidence exists that 
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autophagy can plays an active role in cell death, by contributing to cell death in 
unfavourable settings such as nutrient or growth factors deprivation.  In keeping 
with this, probably c could have a role in the autophagy process.  
To define whether the effect of c on cell cycle progression is a peculiarity of 
lymphoblastoid cells or a more general phenomenon involved in cell growth of 
malignancies of hematopoietic cell lineages, in this study we evaluated whether c 
expression could interfere in cell cycle progression in neoplastic cells.  we 
observed that the amount of cc protein expression in several malignant cell lines 
directly correlates with spontaneous cell growth. We, also, found that the 
knockdown of γc molecule through siRNA is able to decrease the cell 
proliferation rate in these malignancies, thus confirming a direct involvement of 
the molecule as a key player in cell cycle progression.   
Alterations in cell cycle machinery, mainly in the regulation of G1/S phase, are 
known to be associated with the development of solid tumors as well as 
hematological malignant diseases [186].  Of note, cyclins are the key regulators of 
cell cycle progression [172].  In particular, during the G0 to G1 phase transition, 
cyclins D1, D2 and D3 are the first molecules to be induced.  Cyclin A2 gets 
activated during the transition from G1 to S phase and B type cyclins are detected 
during G2 exit and mitosis phase [187].  Namely, cyclins A2 and B1 have been 
implicated in the pathogenesis of cancer and are overexpressed in several tumors 
[188,189].  Evidence indicates that these cyclins are key components of the cell-
cycle machinery [190] and, in particular, cyclin A is expressed at high levels in 
hematopoietic stem cells and is essential for their proliferation [191].  In our 
study, we observed that the expression of A2 and B1 cyclins strongly paralleled 
the proliferative capability of malignant cell lines.  Interestingly, a positive 
correlation between the amount of c and the expression of cyclins A2 and B1 was 
also found.  Taken together these data indicate that the higher is the rate 
proliferation of a certain cell line the higher is the expression of both c and 
cyclins A2 and B1, thus confirming their involvement in the process in a 
concentration dependent fashion.  We also found an increased expression of all D-
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type cyclins in those cell lines that proliferated mostly, K-562 and Molt-4, 
whereas they were not expressed in the other cell lines, but D1 found in Rj225.  
D-type cyclins are strongly expressed in many malignancies.  Overexpression 
of cyclin D1 protein was documented in many forms of cancer, including breast 
cancer [192], while overexpression of cyclin D2 was noted in a wide range of B 
cell malignancies, such as B cell chronic lymphocytic leukemia [193].  Like the 
other D cyclins, cyclin D3 is rearranged and the protein is overexpressed in 
several human lymphoid malignancies.  It was documented that knockdown of 
cyclin D3 inhibits the proliferation of acute lymphoblastic leukemia cells [194].  
However, while A and B type cyclins seem to be vital and necessary components 
of cell cycle progression [191], D-type cyclins may be dispensable for 
proliferation under certain circumstances, in that different cell types are sensitive 
to cyclin D knockdown at a different extent [195].  This would suggest that they 
regulate cell cycle in a cell-type specific manner and that there are alternative 
mechanisms allowing cell cycle progression in a cyclin D-independent fashion 
[195].  Anyway, a critical role for oncogenic transformation of D-type cyclins is a 
well established feature.  
In conclusion, our data demonstrate that γc is strongly implicated in cell cycle 
progression of hematopoietic malignancies.  This biological effect is dependent on 
the expression level of the molecule. Moreover, we documented that the IL-2Rγ 
mRNA levels was also highly expressed in primary leukemic cells, thus 
confirming a direct involvement of the γc in tumor growth. 
These data have been published as Article on International Immunology, for 
the manuscript see below. 
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§ 3.2 ATM and Hyper IgM: cancer predisposition and 
neurodegeneration 
As previously mentioned, the genetic defect underlying the immunodeficiency 
may play a direct role in cancer pathogenesis through genetic mutations in DNA 
DSBs repair systems, which lead to accumulation of mutations that promote 
tumorogenesis. Indeed, an high cancer susceptibility has been reported for ataxia-
telangiectasia (A-T) [196]. The disease is associated with mutations in the ataxia 
telangiectasia mutated (ATM) gene encoding for a 370 kDa serine/threonine 
kinase. The features of A-T include telangiectasia, immune and endocrine 
dysfunctions, cellular radiosensitivity, genomic instability, premature aging, and 
predisposition to cancer [197,198]. The prevalence of cancer in A-T is 10-30%, 
representing the second cause of death [141,199]. Leukemia and lymphoma 
account for about 85% of malignancies [141]. Other solid tumors including 
ovarian cancer, breast cancer, gastric cancer, melanoma and gonadic cancer have 
been described. Patients with A-T also show an increased sensitivity to ionizing 
radiations. The hallmarks of the disease are related to the progressive neurological 
dysfunction, especially affecting the cerebellum and resulting in uncoordinated 
and ataxic movements associated to a deterioration of gross and fine motor skills. 
Recently, an improvement of neurological signs during short-term treatment with 
betamethasone has been reported. To date, the molecular and biochemical 
mechanisms by which the steroid produces such effects have not yet been 
elucidated.  
Other forms of immunodeficiency are associated to cancer predisposition, such 
as the Hyper-IgM (HIGM) syndromes, caused by mutations in the genes encoding 
for the CD40/CD40L interaction pathway leading to defects in the class switch 
recombination.  X-linked hyper-IgM syndrome is associated with a highest risk to 
develop carcinomas of the liver, pancreas, biliary tract and associated 
neuroectodermal endocrine cells [142].   
HIGM is a heterogeneous group of immune defects characterized by normal or 
increased production of IgM contrasting with a marked decrease or an absence of 
other isotypes. Patients with HIGM often present infections by opportunistic 
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intracellular pathogens. Significant neurologic complications, such as cerebral 
toxoplasmosis [200,201] and cryptococcosis [202], are seen in 10-to- 15% of 
affected males.  Malignancies may also occur in patients with HIGM and usually 
affect the biliary tree [143,203] and the gastrointestinal tract in the form of 
neuroendocrine tumours [204]. As in other immunodeficiencies, patients also 
have an increased risk for lymphomas, particularly Hodgkin's disease associated 
with Epstein-Barr virus infection [198]. Furthermore, lymphomas are common in 
forms of HIGM due to DNA repair defects such as Ataxia-telangiectasia and 
Nijmegen Breakage syndrome.  
 We reported the case of a child, in whom a clinical and functional diagnosis of 
Hyper-IgM syndromes was achieved, with a cutaneous B-cells lymphoma 
developed at the age of 12 years. The patient described presented with recurrent 
upper and lower respiratory infections and evidence of suppurative lung disease at 
the conventional chest imaging. The presence of low serum IgG and IgA levels, 
elevated IgM levels, and a marked reduction of in vivo switched memory B cells 
led to a clinical and functional diagnosis of HIGM although the genetic cause was 
not identified. 
The data have been published as Review on The European Journal of 
Neurology, and as Article on Italian Journal of Pediatrics, for the manuscripts see 
below.  
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§3.3 Conclusive remarks 
Through the study of these immunodeficiencies, enormous advances have been 
made in understanding the complex role of genes controlling immunity and other 
process in human, such as cancer and neurodegenetration.   
It’s noteworthy that immune and endocrine systems participate to an integrated 
network of soluble mediators that communicate and coordinate responsive cells to 
achieve effector functions in an appropriate fashion [205]. It has also recently 
been shown a novel dependence of GH signaling on the c cytokines receptor in 
certain cell types, suggesting the interplay between endocrine and immune system 
[206].  There is evidence documenting that immune cells express GH-R [206].  
GH-R can promote cell cycle progression of lymphoid cells and of a wide variety 
of other cells.  Indeed, we documented a direct involvement of c in self-sufficient 
growth and GH induced proliferation in a concentration dependent manner of the 
molecule [148].   
Genes implicated in DNA repair may be implicated in both immune system 
and cancer predisposition as demonstrated by A-T phenotype. ATM plays a key 
role in the control of various cellular processes such as DNA repair, cell cycle 
progression, gene transcription, protein synthesis and degradation and apoptosis. 
This is may be considered a prototype of DNA repair defect syndromes.     
Our data could provide the basis to develop in the near future new therapeutic 
strategies targeting this molecule in cancer therapy.  Moreover, this information 
may also help understand undesired side effects of gene therapy trials. 
These advances offer new insight into the mechanisms involved in immune 
surveillance against phatogens and tumoral cells, which might lead to develop 
new treatments, improving outcomes for affected subjects. 
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TECHNOLOGIES 
§ Cells and cell cultures 
Peripheral Blood Mononuclear cells (PBMC) were obtained from patients and 
healthy donors by Ficoll-Hypaque (Biochrom) density gradient centrifugation.   
Keratinocytes were isolated by incubation of skin fragments in HBSS (Ca2
+
 
Mg2
+
 free) containing 0.75% sodium bicarbonate, 100 mM HEPES (Gibco) 
supplemented with 25 µg/ml Gentamicin with Dispase II (20 mg/ml, Roche).    
Subsequent removal of epidermal sheet with tweezers, followed by incubation for 
10 min at 37°C in 0.05% Trypsin and 0.5 mM EDTA (Gibco).  Trypsin-EDTA 
were stopped adding the same volume of Fetal Bovine Serum (FBS). Cells were 
filtered through double layer gauze sterilized and then washed with DMEM 
containing 10% FBS.  5 x 10
6
 keratinocytes were plated in 100 mm dish pre-
treated with collagen coating solution containing HBSS with 100 µg/ml BSA, 20 
mM HEPES pH 6.5, 30 ug/ml bovine type I collagen isolated from dermis 
(Nutacon).  Cells were grown in supplemented Keratinocyte-SFM medium with 
30 µg bovine pituitary extract and 0.2 ng/ml human rEGF (Gibco) and 100 IU/ml 
Penicillin and 100 g/ml Streptomycin.  The cultures were incubated at 37°C in 
the atmosphere supplemented with 5% CO2, with the cell culture media changed 
daily.  Fibroblasts were isolated by mincing of dermal skin fragments and were 
grown in Dulbecco’s modified Eagle’s medium (Invitrogen) and 10% FBS 
(Gibco), supplemented with 100 U/ml Penicillin and 100 µg/ml Streptomycin 
(Invitrogen).  The cultures were incubated at 37°C in the atmosphere 
supplemented with 5% CO2, with the cell culture media changed daily.  
Moreover, keratinocytes and fibroblasts were passaged fewer than 5 times before 
use in experiments. 
CD34
+ 
hematopoietic stem cells were isolated by incubating 1-2 x 10
8  
PBMCs 
in 300 l of PBE with 100l of CD34 (QBEND 10)-conjugated magnetic beads 
(Multisort beads, Miltenyi Biotec), followed by incubation for 30 min at 4-8°C.  
After incubation, the cells were washed with ice-cold PBE (PBS/0.5% bovine 
serum albumin/5 mM EDTA) and processed through a column placed in a 
magnetic field and the target cells retained.  After washing the column thoroughly 
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with ice-cold PBE, the target cells were recovered by removing the magnetic field 
and flushing the column with 1 ml of PBE.  CD34
+ 
cells were then labeled with a 
CD34-FITC conjugated antibody for 15-20 min at room temperature. 
B lymphoblastoid cell lines (BCLs) were generated by EBV immortalization of 
patients and healthy donors PBMC using standard procedures.   
The human T-acute lymphoblastic leukemia cell line (Molt-4), the chronic 
myelogenous leukemia cell line (K-562), Burkitt lymphoma cell line and its 
isogenic derivatives (Raji and Rj225) were grown in RPMI-1640 (Lonza) 
supplemented with 10% fetal bovine serum (FBS; Gibco), 2 mmol/L L-
glutammine (Gibco), and 50 g/ml gentamycine (Gibco), and cultured at 37°C, 
5% CO2.  Serum starvation was used to synchronize tumor cells in the G0/G1-
phase of the cell cycle.  The cells were incubated in medium without FBS for 24 
hours.  In self-sufficient growth experiments, cells were cultured in DMEM/F12 
(Lonza) without FBS and supplemented with 2 mmol/L L-glutammine.   
Primary leukemic cell lines, consisting of acute lymphoblastic leukemia (ALL) 
cells, were obtained from aspirated bone marrow of 3 patients.  Normal bone 
marrow cells were obtained from healthy donors and used as control cells.   
 
§ SCID-like patient’s profile 
The patient was born at 42 weeks of gestation to unrelated healthy parents.  At 8 
months of age, the patient showed an autoimmune haemolytic anemia and a 
progressive decline of CD4
+
 cells, resulting in a typical lymphocytopenic form of 
severe combined immunodeficiency.  At the time of the study, lymphocytes were 3 
x 10
9
/l, but a severe lymphocyte functional impairment in the absence of HIV or 
any other viral infection was first noted as above described.  IL-2R alterations 
were ruled out.  Thereafter, 2 bronchopneumonia and an interstitial pneumopathy 
occurred despite intravenous Ig replacement therapy and anti-infectious agents.  
Autoreactive antibodies toward smooth muscle, red and white cells were detected.  
During the follow-up, the patient developed a severely progressive active 
autoimmune hepatitis, diagnosed according the AIH international score, treated 
with Azathioprine (AZA) (1.5 mg/kg/day) and steroids.  At 4 years of age the 
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patient died of disseminated interstitial pneumopathy, while the search for a HLA-
matched donor was still pending.   
 
§ Subjects with elevated IgE levels 
Twenty patients with elevated IgE levels and history of allergy were enrolled into 
the study.  Sixteen patients were affected by asthma, 3 of them also by rhinitis, 
and 4 had a history of atopic dermatitis.  The patients divided in two subgroups on 
the basis of IgE levels: group A consisted of 10 patients, 10 males, range of age 5-
15 years, with very high serum IgE levels (>2000kU/l, range 2152-5000 kU/l); 
group B consisted of 10 patients, 9 males, range of age 6-15 years, with high 
serum IgE levels (IgE value between the age specific mean±2SD and 2000 kU/l, 
range 93-1152 kU/l).  Twenty healthy controls, 16 males range of age 6-15 years 
(IgE range 85-100 kU/l), were also studied.  Informed consent was obtained when 
required.  All patients enrolled into the study didn’t receive any treatment, 
including steroid or non-steroid drugs, in the month before entering into the study.  
No difference was found between group A and B in either the number per year or 
the severity of allergic manifestations.  In all patients, the clinical features 
persisted for more than 2 years. 
The Hyper-IgE syndrome (HIES) was excluded by the absence of typical 
clinical and immunological features according to the clinical score for HIES.  In 
particular, no recurrent skin infections, facial, skeletal and dentition anomalies 
were observed.  Other conditions accompanied by elevated serum IgE 
concentration, including AIDS, helminths and parasitic infections were also 
excluded by clinical and laboratoristic features. 
The study has been approved by the Institutional Review Board. 
 
§ Generation of Th1-cell lines  
Th1 cell lines were generated by stimulating PBMC with PHA (8 g/ml) or, in a 
few experiments, with PHA + IFN- (1000 U/ml, ICN, Biomedical, OH) for 72 
hours in complete tissue culture medium.  These cells usually widely express high 
affinity IL-12R. 
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§ Membrane expression of 1 and 2 chains of IL-12R on T cells 
After washing in PBS, cells were incubated for 20 minutes sequentially with 
murine anti-1 or anti-2 chain (25 l) of IL-12R (kindly provided by Dr. Jerome 
Ritz, Dana Farber Cancer Institute, Boston, MA), IgG1 isotype control Ab, 10 l 
FITC-conjugated goat anti-mouse IgG Ab (Becton Dickinson, San Jose, CA), and 
5 l anti-CD4 PE Ab (Becton Dickinson, San Jose, CA).  After staining, the 
expression of IL-12R1 and 2 on CD4+ cells was determined with flow 
cytometer (Becton Dickinson) by gating on the CD4
+
 population.   
 
§ Preparation and characterization of porous scaffolds   
3D porous scaffolds were developed by adapting the phase inversion and salt 
leaching technique. Scaffold morphology was preliminary investigated via 
FESEM Microscopy (Quanta FEG200, FEI).  Specimens were fractured using a 
razor blade along preferential directions, parallel and perpendicular to the surface. 
Transverse and longitudinal sections were covered by a thin chromium layer (ca. 
20 nm) by automatic sputtering (Emitech K575X) to afford a more efficient 
electron conductivity of the scaffold surface.  The porosity was assessed in terms 
of pore size, shape and spatial distribution by images at different magnifications 
and fixed working distance (WD=10 mm).  To obtain a quantitative estimation of 
the scaffold porosity, three different methods were used: weight measurements by 
gravimetric method (GM), 2D image analysis (2D-IA) and mercury intrusion 
porosimetry (MIP). The porosity was obtained by theoretical conditions.  The 2D-
IA evaluation of porosity features (porosity degree, pore size and spatial 
distribution) was performed by dedicated software (ImageJ 1.38b; NIH Freeware; 
National Institutes of Health, Bethesda).  The porosity degree was evaluated from 
the total surface area of counted pores whereas the pore sizes were derived.  Means 
and standard deviations of pore fraction and size were determined on 10 different 
SEM images. Porosity measurements by MIP were assessed to estimate the really 
interconnected pores and their specific pore surface.  A mercury surface tension of 
480 mN/m and a contact angle of 141.38° were used, while a pressure gradient 
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from 400 Pa up to 200 KPa was intruded to exactly count either micro and 
macropores according to the Washburn equation.   
 
§ Scanning Electron Microscopy (SEM)  
As for the investigation of biohybrid scaffold, cells were fixed for 2 h in 2,5% 
glutaraldehyde solution and dehydrated with sequential washes in 50%, 70%, 
80%, 90% and 100% ethanol. The samples were air-dried overnight before the 
chromium sputtering.  In this case, the accelerating voltage of the FESEM 
equipment (Quanta FEG200, FEI) was set at 5 kV, reducing the vacuum level into 
the chamber (LV or Low Vacuum mode), so preventing any negative interaction of 
electron beam with the cellular bodies. 
 
§ siRNA transfection 
The validated chemically modiﬁed oligonucleotides used as siRNA for IL2RG or 
random non-silencing nucleotides with no known specificity siRNA, used as 
negative control, were obtained from Invitrogen.  These siRNAs were transfected 
at a concentration of 200 pmol/1x10
6
 cells in a six well plate for 96 hours.   The 
transfection was performed by lipid vector Lipofectamine 2000 kit (Invitrogen), 
according to the manufacturer’s instructions.  Preliminary experiments were 
performed to establish the silencing efficiency by testing two different 
oligonucleotides obtained from Invitrogen.  The amount of protein expression 
reduction was calculated as follows: 1- (ODsiRNA x 100 / ODcontrol siRNA).  
In self-sufficient growth experiments, BCLs were cultured in Dulbecco 
modified Eagle medium (DMEM)/F12 without FBS and supplemented with 2 
mM/L L-glutamine.
  
  
§ Proliferative assay 
Cell proliferation was analyzed by the thymidine incorporation assay.  
For the evaluation in vitro of proliferative response to mitogens of PMBC, cells 
were stimulated with phytohaemagglutinin (PHA; 8 g/ml), concanavalin A 
(ConA; 8 g/ml), pokeweed (PWM, 10 g/ml) (Difco Laboratories), phorbol-12-
157 
 
myristate-13-acetate (PMA; 20 ng/ml) and ionomycin (0.5 mM) (Sigma Chemical 
Co).  CD3 cross-linking (CD3 X-L) was performed by precoating tissue culture 
plates with 1 and 0.1 ng/ml purified anti-CD3 monoclonal antibody (Ortho 
Diagnostic).   
To evaluate allogeneic response in patients with elevated IgE levels, cells (1 x 
10
5
) were stimulated with an equal amount of irradiated stimulator cells from 
controls in a standard one-way mixed lymphocyte reaction assay.   
Cells were plated in triplicate at 1x10
5
 viable cells/well in 96-well plates (BD 
Biosciences), in 200 l of complete medium for 4 days.  Cultures were pulsed 
with 0.5 Ci 3H-thymidine for 8 hours before harvesting and the incorporated 
radioactivity measured by scintillation counting.   
In a few experiments complement components were inactivated through 
heating of serum samples at 56° C for 30 min before use.  The percentage of 
inhibitory activity in the sera was calculated from the formula: (cpm of PHA-
stimulated cultures containing 5% tested serum/cpm of PHA-stimulated cultures 
containing 5% FCS) x 100.  Patients and normal IgG were purified using a protein 
G column according to the vendor’s instructions (Pharmacia Biotech). 
Cell proliferation was also analyzed by the CFSE dilution assay.  Cells (1x10
6
) 
were resuspended in 1 ml PBS-10% FBS and labeled with 1.7 M CFSE 
(Molecular Probes).  After 2 min in the dark at room temperature, cells were 
washed in FBS and PBS.  After 6 hours cells were analyzed on a FACSCalibur 
flow cytometer using CellQuest software (BD Biosciences). 
Cell viability was determined using trypan blue staining.  Cell survival was 
evaluated following stimulation with anti-Fas mAb (400 ng/ml; Upstate) for 6 
hours. 
 
§ Reagents, western blot and immuneprecipitation 
Recombinant human GH (rGH) was obtained from Serono (Saizer 4).  The 
enhanced chemiluminescence (ECL) kit was purchased from Amersham 
Biosciences.  The Abs anti-c, anti-JAK3, anti-beta-actin, anti-Bcl-2, anti-Bcl-XL, 
anti-histone 3 (H3), anti-phosphotyrosine, anti-STAT5, anti-STAT4 were 
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purchased from Santa Cruz Biotechnology.  The Ab anti-caspase 3 was purchased 
from Cell Signaling Technology.  Acrylamide and bisacrylamide were obtained 
from Invitrogen.  Prestained molecular mass standards were obtained from Bio-
Rad.  Except where noted, other reagents were from Sigma-Aldrich.   
Stimulated or unstimulated cells were washed with ice-cold phosphate buffer 
saline (PBS; Cambrex, Charles City, IA) and lysed in 100 l of lysis solution 
containing 20 mM Tris (pH 8), 137 mM NaCl, 1% Nonidet P-40, 10 mM EDTA, 
1 mM phenylmethylsulfonylfluoride, 1 mM sodium orthovanadatum (Na3VO4), 5 
g/ml leupeptin and 5 g/ml aprotinin on ice for 45 min.  The cell lysates were 
stored at -80°C until processing.  Proteins were separated on 12% SDS-PAGE.  
The membrane was then washed three times in wash buffer and incubated 1 h at 
room temperature or overnight at 4°C with the specific Ab. The membrane was 
then washed three times and an appropriate IgG HRPconjugated secondary Ab 
was used for the second incubation. After further washings, the membrane was 
developed with ECL-developing reagents, and exposed to x-ray films according to 
the manufacturer’s instructions (Amersham Biosciences).   
For immunoprecipitation, lysates were normalized for either protein content or 
cell number and precleared with protein G agarose beads (Amersham 
Biosciences).  The supernatant was incubated with 2 microg/ml anti-JAK3 or 
polyclonal serum, followed by protein G agarose beads.  The immunoprecipitates 
were separated on density gradient gels, followed by Western blotting.  Proteins 
were detected using antibody for phosphotyrosine.  
Densitometric analysis was performed after background equalization through 
the ImageJ software.    
 
§ Confocal microscopy 
After appropriate stimulation, as indicated, cells were fixed in 4% 
paraformaldehyde in 0.1 M phosphate buffer (pH 7.0) for 30 min at room 
temperature and centrifuged in a Shandon Cytospin III (Histotronix) onto a glass 
slide and permeabilized by incubation in a 0.2% Triton X-100 solution for 20 min.  
BCLs were incubated for 1 h at room temperature with rabbit anti-STAT5 Ab in 
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PBS containing 1% BSA.  After four washings for 5 min in PBS, the cells were 
incubated for 1 h at room temperature with FITC-conjugated donkey anti-rabbit 
IgG (Pierce) in PBS. After washing in PBS, the glass slides were mounted under a 
coverslip in a 5% glycerol PBS solution. The slides were analyzed by laser 
scanning confocal microscopy using a Zeiss LSM 510 version 2.8 SP1 Confocal 
System (Zeiss).  At least 100 cells per condition were analyzed in each experiment 
to determine the rate of STAT5 nuclear translocation. 
 
§ PCR and quantitative real-time PCR analysis  
The cells cultured on each PCL construct were extracted from the scaffold by 
aspiration of the medium and flushing of the matrix at the different time point.  
RNA extraction was performed using RealTime ready Cell Lysis Kit (Roche 
Applied Science) according to the manufacturer’s instructions.  Total RNA was 
reverse transcribed using the Transcriptor High Fidelity cDNA Synthesis Kit 
(Roche Applied Science) according to the manufacturer’s protocol using random 
hexameric primers.  Amplification of the cDNAs was performed using the SYBR 
Green and analyzed with the Light Cycler480 (Roche) under the following 
conditions: 5 min of denaturation at 94°C followed by 55 cycles for 6 s of 
annealing at 62°C and 5 min of extension at 72°C.  Real-time PCR utilized 
specific primers to amplify Ikaros, TAL1, Spi-B, PTCRA and RAG2 (Table 1).  
β-actin was used as a reference gene. 
To evaluate the effect of c on cell survival and proliferation, RNA was 
reverse-transcribed in the presence of SuperScript II RT (Invitrogen) and 
oligo(dT) primers (Invitrogen) at 50°C for 50 min and then at 85°C for 5 min to 
inactivate the enzymes.  Amplification of the cDNAs was performed using the 
SYBR Green and analyzed with the Light Cycler480 (Roche).  Primers are listed 
in Table 1.  The PCR conditions comprised an initial denaturation at 94°C for 5 
min, followed by 35 cycles at 62°C for 20 s and 72°C for 5 min.  A dissociation 
procedure was performed to generate a melting curve for confirmation of 
amplification specificity.  The results were normalized to beta-actin.  The relative 
levels of gene expression are represented as -Ct=(Ctgene-Ctreference) and the fold 
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change in gene expression was calculated by the 2
-Ct
 method (where Ct is cycle 
threshold), as previously described. 
 
Gene Primers sequence 5'-3' 
Ikaros 
 
5'- TCCCAAGTTTCAGGGAAGGA -3' 
5'- ACGACTCTGTCACTCTTGGAGCT -3' 
TAL1 
5'- TCTGAAGCAAGGCGGTGGAC -3' 
5'- GGAAGACCGTGCCGTCTTCA -3' 
Spi-B 
5'- TCGCCCTGGAGGCTGCAC -3' 
5'- CCCCCTCTGAATCAGGGTA -3' 
PTCRA 
5'- CATCCTGGGAGCCTTTGGT -3' 
5'- CCGGTGTCCCCCTGAGAG -3' 
RAG2 
5'- CCTGAAGCCAGATATGGTC -3' 
5'- GTGCAATTCACAGCTGGGCT -3' 
Bcl-XL 
5'-GTAAACTGGGGTCGCATTGT-3' 
5'-TGCTGCATTGTTCCCATAGA-3' 
Cyclin D1 
5'-AGGTCTGCGAGGAACAGAAGTG-3' 
5'-TGCAGGCGGCTCTTTTTC-3' 
Cyclin D2 
5'-CTGTGTGCCACCGACTTTAAGTT-3' 
5'-GATGGCTGCTCCCACACTTC-3' 
Cyclin D3 
5'-GCAGCGCCTTTCCCAACT-3' 
5'-TCAAAAGGAATGCTGGTGTATGTATC-3' 
Cyclin A2 
5'-CTGCTGCTATGCTGTTAGCC-3' 
5'-TGTTGGAGCAGCTAAGTCAAAA-3' 
Cyclin B1 
5'-CGGGAAGTCACTGGAAACAT-3' 
5'-AAACATGGCAGTGACACCAA-3‘ 
IL-2R 
5'-TGCTAAAACTGCAGAATCTGGT-3' 
5'-AGCTGGGATTCACTCAGGTTTG-3' 
Beta-actin 
5'-GACAGGATGCAGAAGGAGAT-3' 
5'-GACAGGATGCAGAAGGAGAT-3' 
 
Table 1. Primers used for real-time qRT-PCR 
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To evaluate IL-12R2 chain expression, RNA was reverse transcribed into 
cDNA using ExpandTM Reverse transcriptase according to the manufacturer's 
protocol (Boehringer Manneheim).  The cDNA was PCR amplified (94°C, 1 
minute; 55°C, 1 minute; 72°C,1 minute for 30 cycles) using specific primers for 
IL-12R2: sense primer GGAGAGATGAGGGACTGGT and antisense primer 
TCACCAGCAGCTGTCAGAG.  To monitor the amount of RNA, -actin mRNA 
expression was used.  PCR products were separated in a 1% agarose gel and 
viewed after ethidium bromide staining.  
 
§ Flow cytometry analysis 
At defined time-points (0, 1, 2, 3 and 4 w), the cells cultured on each of the PCL 
construct were extracted from the scaffolds by aspiration of the medium and 
flushing of the matrices.  Cells were exposed to directly-conjugated mouse anti-
human monoclonal antibodies (mAbs) to asses hematopoietic stem cells with 
CD34-APC (BD Biosciences), CD45-APC-Cy7 (BD Biosciences), and 
lymphocyte precursors with CD7-PE (Immunological Sciences), CD1a-FITC 
(DAKO), CD3-PerCP (BD Biosciences), CD4-PE (BD Biosciences), CD8-PECy7 
(Beckman Coulter).  The cells were incubated with directly-labelled antibody 
clones at 4°C in the dark for 30 min, washed and resuspended in 100 ml PBS.  
The events in the displayed graphs and dot plots were gated by forward and side 
scatter to exclude dead cells. For analysis of early thymocyte subsets with CD7, 
CD3, CD4 and CD8 T-cell precursors were identified by gating on viable CD45+ 
cells. Analytical flow cytometry was performed using a BD FACS Canto II flow 
cytometer (BD Biosciences).  Subsequent data processing and preparation for 
presentation was done using BD FACSDiva software. 
 
§ Statistical analysis 
All statistical analyses were performed using GraphPad Prism 4.00 and MedCalc 
for Windows.  All data were expressed as mean ± standard deviation.  Values of p 
< 0.05 were considered statistically signiﬁcant. 
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SUMMARY 
 
The immune response is composed of a diverse network of defenses, 
including cellular components and soluble mediators. A proper immune 
response relies on the innate immunity, characterized by a rapid and 
nonspecific initial response to infections and later on the adaptive 
immunity, characterized by a specific response to a particular antigen. 
Failure of host defense may occur, causing the dysregulation of  the 
immune system, in particular the onset of immunodeficiency, autoimmunity 
and cancer predisposition. 
Primary immunodeficiencies comprise more than 200 different disorders 
that affect the development and the functions of the immune system.  Many 
scientific papers have been published on the molecular and cellular basis of 
the immune response and on the mechanisms involved in the correct 
development of immune system components.  Although today the genetic 
and molecular basis of the principal mechanisms involved in the immune 
response are well known, some aspect in this field remain unclear.   
In this thesis, during the three years of my PhD program, I have 
contributed to elucidate “Primary Immunodeficiencies: novel insight in 
pathogenesis and potential therapeutic approach”, through the combination 
of clinical, cellular, functional and molecular approaches. 
In particular, my research work is focused on the deepening of the 
knowledge on thymic ontogeny, in particular on the study of the functional 
role of FOXN1 transcription factor in the development of the T-cell 
ontogeny and new strategy to develop an in vitro thymic organoid.  
Moreover, I participate to give a contribution to better define the 
regulatory mechanisms of the immune system, with particular regard to the 
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central and peripheral tolerance, whom impairment function leads to 
autoimmunity.   
Finally, I also participated to better define the role of the immune system 
genes, whom alteration induce the development of cancer predisposition, 
endocrine system failure and neurodegeneration. In particular I studied the 
role of c in cell cycle progression, strongly related to its cellular amount 
and GH-R signaling, defining the basis of the physiological interaction 
between endocrine and immune systems, and the role ATM in the 
progressive neurological dysfunction. 
Overall, all my studies were designed in order to clarify unsolved issues 
and unknown mechanisms underlying the functionality of the immune 
system.  These results could be useful both in the clinical practice and in the 
basic research of immunedysregulation.   
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